16-2084328-G-A
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 0P and 7B. BP4_ModerateBP6BS2
The NM_000548.5(TSC2):c.4106G>A(p.Arg1369Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000753 in 1,460,376 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R1369W) has been classified as Likely benign.
Frequency
Consequence
NM_000548.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TSC2 | NM_000548.5 | c.4106G>A | p.Arg1369Gln | missense_variant | 34/42 | ENST00000219476.9 | NP_000539.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TSC2 | ENST00000219476.9 | c.4106G>A | p.Arg1369Gln | missense_variant | 34/42 | 5 | NM_000548.5 | ENSP00000219476 |
Frequencies
GnomAD3 genomes Cov.: 34
GnomAD3 exomes AF: 0.0000241 AC: 6AN: 248622Hom.: 0 AF XY: 0.0000222 AC XY: 3AN XY: 135142
GnomAD4 exome AF: 0.00000753 AC: 11AN: 1460376Hom.: 0 Cov.: 33 AF XY: 0.00000826 AC XY: 6AN XY: 726478
GnomAD4 genome Cov.: 34
ClinVar
Submissions by phenotype
Tuberous sclerosis 2 Uncertain:1Benign:2
Uncertain significance, criteria provided, single submitter | clinical testing | New York Genome Center | Jan 08, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 07, 2021 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 27, 2024 | - - |
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | Feb 16, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 30, 2023 | The p.R1369Q variant (also known as c.4106G>A), located in coding exon 33 of the TSC2 gene, results from a G to A substitution at nucleotide position 4106. The arginine at codon 1369 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
TSC2-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 11, 2024 | The TSC2 c.4106G>A variant is predicted to result in the amino acid substitution p.Arg1369Gln. This variant was reported in an individual with autism spectrum disorder (Table S3, Saskin et al. 2017. PubMed ID: 28250423; g.2074330 hg18 in Table 1, Schaaf et al. 2011. PubMed: 21624971). However, the variant was also reported in a healthy control (g.2134329 hg19 in Table S1, Bodian et al. 2014. PubMed ID: 24728327). This variant is reported in 0.011% of alleles in individuals of East Asian descent in gnomAD and has conflicting interpretations ranging from uncertain to benign in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/135386/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
not specified Other:1
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at